Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Shoshana, Eitan"'
Autor:
Roanna A. Debler, Caitlin A. Madison, Lauren Hillbrick, Paula Gallegos, Stephen Safe, Robert S. Chapkin, Shoshana Eitan
Publikováno v:
Journal of Affective Disorders. 333:409-419
Autor:
Caitlin A, Madison, Roanna A, Debler, Nathan I, Vardeleon, Lauren, Hillbrick, Arul, Jayaraman, Stephen, Safe, Robert S, Chapkin, Shoshana, Eitan
Publikováno v:
Journal of Affective Disorders. 319:213-220
Our recent study demonstrated that selective aryl hydrocarbon receptor modulators (SAhRMs), such as 1,4-dihydroxy-2-napthoic acid (DHNA) act as antidepressants in female mice. Given that some effects of certain SAhRMs are known to also be mediated vi
Autor:
Caitlin A. Madison, Jacob Kuempel, Georgia Lee Albrecht, Lauren Hillbrick, Arul Jayaraman, Stephen Safe, Robert S. Chapkin, Shoshana Eitan
Publikováno v:
J Affect Disord
BACKGROUND: Current pharmaceutical treatments for depression are sometimes ineffective and may have unwanted side effects that interfere with patient compliance. This study examined the potential antidepressant-like effects of dietary- and microbial-
Publikováno v:
Neuroscience & Biobehavioral Reviews. 127:284-295
Opioids are highly efficacious in their ability to relieve pain, but they are liable for abuse, dependence, and addiction. Risk factors to develop opioid use disorders (OUD) include chronic stress, socio-environment, and preexisting major depressive
Autor:
Caitlin A. Madison, Lauren Hillbrick, Jacob Kuempel, Georgia Lee Albrecht, Kerstin K. Landrock, Stephen Safe, Robert S. Chapkin, Shoshana Eitan
Publikováno v:
Behavioural brain research. 440
The aryl hydrocarbon receptor (AhR) is a key regulator in the microbiome-gut-brain axis, and AhR-active microbial metabolites modulate multiple neuronal responses. We recently demonstrated that 3,3'-diindolylmethane (DIM) and 1,4-dihydroxy-2-naphthoi
Publikováno v:
Journal of Psychopharmacology. 34:771-777
Background: Opioids are commonly prescribed to treat moderate-to-severe pain. However, their use can trigger the development of opioid use disorder. A major problem in treating opioid use disorder remains the high rate of relapse. Aim: The purpose of
Publikováno v:
ACS Chemical Neuroscience. 11:1955-1964
Chronic use of opioids can lead to tolerance, dependence, abuse, and addiction. This in turn can result in dose escalation and opioid overdose. Opioid overdose can be fatal due to severe opioid-induced respiratory depression (OIRD). Naloxone, a nonsp
Publikováno v:
Behavioural Pharmacology. 31:293-307
Social environment influences the trajectory of developing opioid use disorder (OUD). Thus, the present study tested the hypothesis that sociability levels will affect the responses to opioids. Mice were tested for their baseline sociability, anxiety
Autor:
Shoshana Eitan, Caitlin A Madison
Publikováno v:
Psychological medicine. 50(6)
BackgroundDepression and post-traumatic stress disorder (PTSD) are leading causes of disability and loss of life by suicide. Currently, there are less than satisfactory medical solutions to treat these mental disorders. Here, we explore recent precli
Publikováno v:
Drug and Alcohol Dependence. 188:113-118
Background The association with opioid-abusing individuals or even the perception of opioid abuse by peers are risk factors for the initiation and escalation of abuse. Similarly, we demonstrated that morphine-treated animals housed with only morphine